A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Summary
Third Opinion Trial Synopsis:
This study wants to see if a new medicine called talquetamab, when used with other medicines, works better than one medicine called daratumumab and another called pomalidomide. The study will also compare talquetamab with daratumumab when used with different medicines. The goal is to see which combination of medicines works best to help people feel better.
This study wants to see if a new medicine called talquetamab, when used with other medicines, works better than one medicine called daratumumab and another called pomalidomide. The study will also compare talquetamab with daratumumab when used with different medicines. The goal is to see which combination of medicines works best to help people feel better.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: